<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">48474</article-id><article-id pub-id-type="doi">10.7554/eLife.48474</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-150811"><name><surname>Thomson</surname><given-names>Benjamin R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6565-5866</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-144683"><name><surname>Carota</surname><given-names>Isabel A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7980-2377</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-144684"><name><surname>Souma</surname><given-names>Tomokazu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3285-8613</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-144685"><name><surname>Soman</surname><given-names>Saily</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41846"><name><surname>Vestweber</surname><given-names>Dietmar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3517-732X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-6599"><name><surname>Quaggin</surname><given-names>Susan E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3706-5727</contrib-id><email>quaggin@northwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Feinberg Cardiovascular and Renal Research Institute</institution><institution>Northwestern University Feinberg School of Medicine</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Division of Nephrology and Hypertension</institution><institution>Northwestern University Feinberg School of Medicine</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Max Planck Institute for Molecular Biomedicine</institution><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier Y</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute for Heart and Lung Research</institution><country>Germany</country></aff></contrib><contrib contrib-type="editor"><name><surname>Smith</surname><given-names>Lois</given-names></name><role>Reviewing Editor</role><aff><institution>Boston Children's Hospital, Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Division of Nephrology, Duke University School of Medicine, Durham, United States</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>17</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e48474</elocation-id><history><date date-type="received" iso-8601-date="2019-05-15"><day>15</day><month>05</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-10-11"><day>11</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Thomson et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Thomson et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-48474-v2.pdf"/><abstract><p>Elevated intraocular pressure (IOP) due to insufficient aqueous humor outflow through the trabecular meshwork and Schlemm’s canal (SC) is the most important risk factor for glaucoma, a leading cause of blindness worldwide. We previously reported loss of function mutations in the receptor tyrosine kinase TEK or its ligand ANGPT1 cause primary congenital glaucoma in humans and mice due to failure of SC development. Here, we describe a novel approach to enhance canal formation in these animals by deleting a single allele of the gene encoding the phosphatase PTPRB during development. Compared to <italic>Tek</italic> haploinsufficient mice, which exhibit elevated IOP and loss of retinal ganglion cells, <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>+/-</sup> mice have elevated TEK phosphorylation, which allows normal SC development and prevents ocular hypertension and RGC loss. These studies provide evidence that PTPRB is an important regulator of TEK signaling in the aqueous humor outflow pathway and identify a new therapeutic target for treatment of glaucoma.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>glaucoma</kwd><kwd>Schlemm's canal</kwd><kwd>Tie2</kwd><kwd>VE-PTP</kwd><kwd>endothelium</kwd><kwd>TEK</kwd><kwd>PTPRB</kwd><kwd>angiopoietin</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 HL124120</award-id><principal-award-recipient><name><surname>Quaggin</surname><given-names>Susan E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 EY025799</award-id><principal-award-recipient><name><surname>Quaggin</surname><given-names>Susan E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30 DK114857</award-id><principal-award-recipient><name><surname>Quaggin</surname><given-names>Susan E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic deletion of one <italic>Ptprb</italic> allele leads to increased phosphorylation of the TEK receptor, increasing Schlemm's canal area and protecting retinal ganglion cells in a mouse model of glaucoma.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>A leading cause of blindness worldwide, glaucoma is a devastating disease with no cure. Elevated intraocular pressure (IOP) caused by defects in the aqueous humor outflow (AHO) pathway is the most important risk factor for disease progression and vision loss (<xref ref-type="bibr" rid="bib10">Coleman and Miglior, 2008</xref>; <xref ref-type="bibr" rid="bib4">Becker, 1961</xref>). Indeed, IOP reduction is currently the only therapeutic intervention proven to slow glaucoma progression in patients. In both humans and mice, the majority of AHO occurs through the conventional route (<xref ref-type="bibr" rid="bib16">Johnson et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Toris et al., 1999</xref>; <xref ref-type="bibr" rid="bib40">Toris et al., 2000</xref>; <xref ref-type="bibr" rid="bib24">Millar et al., 2011</xref>; <xref ref-type="bibr" rid="bib25">Millar et al., 2015</xref>), comprised of the trabecular meshwork (TM) and the large, lymphatic-like Schlemm’s canal (SC) located in the iridocorneal angle (<xref ref-type="bibr" rid="bib16">Johnson et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Park et al., 2014</xref>; <xref ref-type="bibr" rid="bib2">Aspelund et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Kizhatil et al., 2014</xref>). Aqueous humor from the anterior chamber enters SC through the TM and is drained through a series of collector channels into the episcleral veins and systemic circulation. Recent studies have identified the importance of endothelial signaling molecules in development and maintenance of SC and the conventional outflow pathway, and critical roles have been described for the endothelial transcription factor PROX1 (<xref ref-type="bibr" rid="bib27">Park et al., 2014</xref>) as well as the VEGFR2/3 (<xref ref-type="bibr" rid="bib21">Kizhatil et al., 2014</xref>; <xref ref-type="bibr" rid="bib2">Aspelund et al., 2014</xref>) and TEK (<xref ref-type="bibr" rid="bib36">Thomson et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>) receptor tyrosine kinase signaling pathways.</p><p>TEK (Tunica interna endothelial cell kinase, also known as TIE2) is the tyrosine kinase receptor for the angiopoietin (Angpt) ligands ANGPT1, ANGPT2 and ANGPT4 (<xref ref-type="bibr" rid="bib30">Saharinen et al., 2017</xref>). The Angpt-TEK pathway is essential for SC development and maintenance, and loss of function mutations in <italic>TEK </italic>or the gene encoding its primary ligand <italic>ANGPT1</italic> have been identified in patients with primary congenital glaucoma, a severe form of glaucoma characterized by early/childhood onset, buphthalmos and optic neuropathy (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Kabra et al., 2017</xref>). Furthermore, recent genome-wide association studies have identified risk variants linked to the TEK signaling pathway in adults with elevated IOP and open angle glaucoma, the most common form of glaucoma worldwide (<xref ref-type="bibr" rid="bib18">Khawaja et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Gao et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">MacGregor et al., 2018</xref>).</p><p>In mice, post-natal <italic>Tek</italic> deletion leads to complete failure of SC development and rapidly progressing glaucoma (<xref ref-type="bibr" rid="bib36">Thomson et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>). A similar disease is observed in mice lacking the TEK ligand ANGPT1, confirming that ANGPT-TEK signaling is essential for canal development (<xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>). Importantly, while <italic>Tek</italic> knockout mice exhibit complete loss of SC, a hypomorphic canal characterized by focal narrowing and convolutions is observed in haploinsufficient animals (<italic>Tek</italic><sup>+/-</sup> mice) (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>). This hypomorphic SC is associated with moderate IOP elevation, indicating a clear dose-dependent effect of TEK signaling in development and function of the aqueous outflow pathway and suggesting that TEK activation using genetic or pharmacological approaches might provide novel treatments for patients with high-pressure glaucoma. Indeed, the clear dose-dependent relationship between ANGPT-TEK signaling and severity of disease presentation in rodent models supports the argument that therapeutic modulation of this pathway will be efficacious in patients (<xref ref-type="bibr" rid="bib29">Plenge et al., 2013</xref>).</p><p>Activation of the TEK receptor has been achieved in vitro and in vivo either by increasing activity of endogenous ANGPT ligands, providing ANGPT recombinant proteins (<xref ref-type="bibr" rid="bib19">Kim et al., 2005</xref>; <xref ref-type="bibr" rid="bib34">Souma et al., 2018</xref>), or by suppression of the phosphatase PTPRB (also known as the Vascular Endothelial Protein Tyrosine Phosphatase, VE-PTP) (<xref ref-type="bibr" rid="bib42">Winderlich et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Shen et al., 2014</xref>; <xref ref-type="bibr" rid="bib9">Carota et al., 2019</xref>), which strongly dephosphorylates TEK (<xref ref-type="bibr" rid="bib34">Souma et al., 2018</xref>; <xref ref-type="bibr" rid="bib12">Fachinger et al., 1999</xref>). PTPRB inhibition results in ligand-independent increased TEK phosphorylation at all phosphorylated tyrosine residues, and leads to a dramatic increase in downstream signaling (<xref ref-type="bibr" rid="bib34">Souma et al., 2018</xref>; <xref ref-type="bibr" rid="bib9">Carota et al., 2019</xref>). Here, we show that developmental deletion of a single <italic>Ptprb</italic> allele in mice is sufficient to reduce PTPRB expression and leads to increased TEK activation in vivo. Furthermore, in <italic>Tek</italic><sup>+/-</sup> haploinsufficient mice, this increased TEK activation is sufficient for normal SC development, preventing both ocular hypertension and retinal ganglion cell (RGC) loss.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>To increase the level of TEK phosphorylation in vivo, we utilized a <italic>Ptprb</italic><sup>NLS-LacZ</sup> knock-in reporter allele (<xref ref-type="bibr" rid="bib3">Bäumer et al., 2006</xref>) to delete a single allele of the <italic>Ptprb</italic> gene. This construct incorporates a β-Galactosidase cDNA tagged with a nuclear localization signal in place of the first exon of <italic>Ptprb</italic>, preventing production of PTPRB protein. As previously described, heterozygous <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice are born normally (<xref ref-type="bibr" rid="bib3">Bäumer et al., 2006</xref>), although expression of PTPRB was reduced by approximately 50% (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, uncropped images presented as <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Likewise, <italic>Tek</italic> heterozygosity resulted in approximately 50% reduction in TEK protein detected in lung lysate (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Reductions in phosphatase abundance had a direct effect on TEK activation and <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice showed approximately a 118% increase in phosphorylated TEK when measured in lung tissue using an immunoprecipitation assay (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, uncropped images presented as <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), confirming our hypothesis that changes in PTPRB expression would have a direct impact on TEK phosphorylation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Deletion of one <italic>Ptprb</italic> allele leads to increased TEK phosphorylation.</title><p>(<bold>A</bold>) Western blot of lung lysate from P5 Control, <italic>Tek</italic><sup>+/-</sup>, <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> and <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice revealed a 50% reduction in PTPRB expression in <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> (heterozygous) and <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice. Likewise, TEK expression was reduced approximately 50% in <italic>Tek</italic><sup>+/-</sup> and <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice. (<bold>B</bold>) Immunoprecipitation of lung lysates from adult control and <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> using anti-TEK antibody followed by western blotting with anti-phospho tyrosine antibody revealed a marked elevation of TEK phosphorylation in <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals compared to littermate controls. Horizontal lines indicate population means. *p&lt;0.05, ***p&lt;0.001 as determined by Student’s t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48474-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Uncropped images corresponding to the western blots presented in <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48474-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Uncropped images corresponding to the western blots presented in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48474-fig1-figsupp2-v2.tif"/></fig></fig-group><p>The finding that <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> haploinsufficient mice exhibited markedly increased TEK phosphorylation suggested that these animals would provide a powerful tool to study the effect of PTPRB blockade on SC development in the context of reduced TEK signaling. Therefore, we crossed mice carrying the <italic>Ptprb</italic><sup>NLS-LacZ</sup> allele with a previously-described mouse model of <italic>Tek</italic> heterozygosity, creating a constitutive model of <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> double haploinsufficency. Adult <italic>Tek</italic> haploinsufficient mice have been reported to exhibit a hypomorphic SC insufficient for normal AHO, leading to moderate IOP elevation (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>). To test our hypothesis that ~50% reduction of PTPRB activity might prevent the glaucoma phenotype in <italic>Tek<sup>+/-</sup></italic> mice without the need to increase ligand availability, <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> double heterozygous mice were generated, and enucleated eyes were collected. After fixation, eyes were prepared for whole-mount immunostaining and visualized using confocal microscopy. Consistent with previous findings (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>), analysis of CD31-positive SC area revealed a hypomorphic canal phenotype in adult <italic>Tek</italic> heterozygous mice when compared to littermate controls (Control: 29,974 ± 2145, <italic>Tek</italic><sup>+/-</sup>: 17,457 ± 1040 μm<sup>2</sup>/20x field; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). This phenotype was abrogated by deletion of a single <italic>Ptprb</italic> allele in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals, which exhibited normal SC area (<italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>: 23,848 ± 1574 μm<sup>2</sup>/20x field). Importantly, despite elevated TEK activation, <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals displayed a normal SC (<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>: 28,175 ± 1668 μm<sup>2</sup>/20x field), suggesting reduction of PTPRB function is well tolerated during SC development in the absence of other mutations.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>TEK signaling has a dose-dependent effect on Schlemm’s canal (SC) area and development.</title><p>(<bold>A</bold>) Confocal microscopy of whole mount eyes revealed reduced CD31+ SC area in adult <italic>Tek</italic><sup>+/-</sup> haploinsufficient mice. This phenotype was blunted in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> double heterozygous animals, confirming the importance of TEK activation in canal development. <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> heterozygous controls had normal SC area (n = 8 WT, 12 <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>, 11 <italic>Tek</italic><sup>+/-</sup> and 11 <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice). 20x fields shown represent an area of 65,536 μm<sup>2</sup>. Images were captured as 10-frame Z stacks with a step size of 1.67 μm and a pinhole of 1.2 Airy units, and are shown as maximum intensity projections. (<bold>B</bold>, quantified in <bold>C</bold>) At postnatal day 5 (P5), confocal microscopy of the developing SC in eye whole mounts revealed reduced numbers of proliferating Ki-67-positive SC ECs (Ki67-PROX1 double positive cells) in <italic>Tek</italic> haploinsufficient animals compared to littermate WT or <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> controls. Normal proliferation was observed in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals. (<bold>D</bold>) Compared to control and <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice, PROX1 expression was reduced in <italic>Tek</italic><sup>+/-</sup> littermate eyes. Expression was normal in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> double heterozygotes. n = 8 (WT), 4 (<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>), 8 (<italic>Tek</italic><sup>+/-</sup>) and 5 (<italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>) Shown are maximum intensity projections from 8-frame confocal Z stacks captured using a 20x objective, step size of 1 μm and pinhole of 1.2 Airy units. Norm. AFU: Normalized, background subtracted arbitrary fluorescence units. (<bold>E</bold>) Compared to control and <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> littermates, confocal analysis of adult SC revealed a marked increase in the number of focal convolutions and narrowings in the eyes of <italic>Tek</italic><sup>+/-</sup> and <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice. N = 4 (WT), 7 (<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>), 5 (<italic>Tek</italic><sup>+/-</sup>) and 6 (<italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>). Horizontal lines indicate population means. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 as determined by 1-way ANOVA followed by Bonferroni’s correction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48474-fig2-v2.tif"/></fig><p>Developmental haploinsufficency of <italic>Tek</italic> and <italic>Ptprb</italic> had clear effects on adult SC area in our model. To determine if this phenotype was due to altered proliferation of SC endothelial cells (ECs), we next analyzed eyes collected at P5 when SC development is underway. In <italic>Tek</italic><sup>+/-</sup> eyes, we observed a marked reduction in the proportion of PROX1+ SC ECs which were also positive for Ki-67 (Control: 0.302 ± 0.022, <italic>Tek</italic><sup>+/-</sup>: 0.214 ± 0.016), suggesting that the hypomorphic canal phenotype in these animals may be due to reduced proliferation during canal development (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, quantified in <bold>C</bold>). Strikingly, normal proliferation of PROX1+ SC cells was observed in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice (<italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>: 0.345 ± 0.039), providing a potential mechanism for the observed effects on canal area in adulthood. A similar effect was observed on PROX1 expression, which was dramatically decreased in the SC of <italic>Tek</italic><sup>+/-</sup> eyes at P5 and appeared normal in the eyes of <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> littermates (Norm. AFU: Control: 1.0 ± 0.12, <italic>Tek</italic><sup>+/-</sup>: 0.49 ± 0.07, <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>: 0.82 ± 0.065, <xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><p>In addition to decreased area, <italic>Tek</italic><sup>+/-</sup> SCs are characterized by focal thinning and convolutions which are not present in WT littermates (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>) (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Interestingly, although <italic>Ptprb</italic> haploinsufficency resulted in increased proliferation and expanded canal area in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals, these focal defects were still observed—suggesting that directional signaling may play a role in proper canal formation which cannot be recapitulated by nonspecific TEK activation.</p><p>We next examined the effect of altered SC area in <italic>Tek</italic><sup>+/-</sup> and <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice on aqueous humor homeostasis. <italic>Tek</italic> heterozygous mice on an outbred background were found to have elevated IOP at 30 weeks of age (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, Control: 13.7 ± 0.23, <italic>Tek</italic><sup>+/-</sup> 18.15±0.33 mmHg). Consistent with observations of SC morphology, while <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice had normal IOP (13.81 ± 0.82 mmHg), incorporation of this allele into the <italic>Tek</italic><sup>+/-</sup> model was beneficial and blunted the ocular hypertension associated with <italic>Tek</italic> haploinsufficiency, despite the presence of focal morphological defects (<italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> IOP: 14.92 ± 0.31 mmHg). To confirm the impact of the <italic>Ptprb</italic><sup>NLS-LacZ</sup>-induced IOP reduction on the retina, we counted BRN3B positive ganglion cells in an additional cohort of mice at 19 weeks of age (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). While <italic>Tek</italic> heterozygous mice showed a marked reduction in RGCs, this loss did not occur in <italic>Tek</italic><sup>+/</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>Ptprb</italic> heterozygosity prevents ocular hypertension and RGC loss in <italic>Tek</italic> haploinsufficient mice.</title><p>(<bold>A</bold>) Elevated intraocular pressure (IOP) was observed in <italic>Tek</italic><sup>+/-</sup> haploinsufficient mice at 30 weeks of age when measured by rebound tonography. As in <xref ref-type="fig" rid="fig2">Figure 2</xref>, this phenotype was prevented in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> double heterozygous animals, confirming the importance of TEK activation in IOP homeostasis (n = 6 WT, 14 <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>, 12 <italic>Tek</italic><sup>+/-</sup> and 14 <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice). (<bold>B</bold>) BRN3B staining in retinal flat-mounts from a second group of mice revealed loss of retinal ganglion cells by 19 weeks in <italic>Tek</italic><sup>+/-</sup> mice. Littermate <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals were protected, correlating with the reduced IOP observed (n = 4 WT, 4 <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>, 3 <italic>Tek</italic><sup>+/-</sup> and 4 <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice). Horizontal lines indicate population means. *p&lt;0.05, ***p&lt;0.001 as determined by 1-way ANOVA followed by Bonferroni’s correction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48474-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Retinal vasculature was normal in <italic>Tek</italic> and <italic>Ptprb </italic>haploinsufficient mice.</title><p>(<bold>A</bold>) Confocal microscopy of P5 retinas stained with anti-CD31 antibody reveal normal progression of the superficial vasculature at both arterial and venous sprouting fronts. n = 6 (WT), 5 (<italic>Tek</italic><sup>+/-</sup>), 3 (<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>), and 3 (<italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>). Horizontal lines indicate population means. Lack of significance was determined by 1-way ANOVA followed by Bonferroni’s correction. (<bold>B</bold>) Normal, fully developed retinal vasculature was observed in all three plexus layers in mice of all genotypes at P20. Scale bars indicate 250 μm in all panels.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48474-fig3-figsupp1-v2.tif"/></fig></fig-group><p>TEK signaling is critical for retinal angiogenesis, and to exclude the possibility that vascular defects and subsequent ischemia were responsible for RGC loss in <italic>Tek</italic><sup>+/-</sup> mice, we examined vascular morphology in our animals. We first examined retinas collected at P5, when development of the superficial vasculature is ongoing. At this timepoint, CD31 staining revealed normal progress of the angiogenic sprouting front in <italic>Tek</italic><sup>+/-</sup>, <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>, and <italic>Tek</italic><sup>+/</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice when compared to littermate controls (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). At P20, when development of the mature retinal vasculature is complete, we observed normal patterning in all three retinal vascular layers in mice of all genotypes (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). By this timepoint, hyaloid vessels were not observed in animals of any genotype. Taken together, these data suggest that blunted IOP elevation in <italic>Tek</italic><sup>+/</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals likely had a direct impact on glaucoma pathogenesis in our model and that retinal ischemia is unlikely to account for the RGC loss observed in Tek haploinsufficient mice.</p></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Ocular hypertension is the single most important risk factor for glaucoma in patients, and reducing IOP is the only therapeutic intervention proven to slow disease progression. Although aqueous humor flow through the conventional (trabecular) outflow pathway represents the majority of AHO, drugs targeting this outflow pathway were not available until the recent introduction of the Rho kinase inhibitors ripasudil and netarsudil. However, while these molecules provide exciting new treatment options, clinical trials have not shown them to be superior to current standard of care therapies for lowering IOP (<xref ref-type="bibr" rid="bib35">Tanna and Johnson, 2018</xref>), underscoring the need for additional drug targets and treatment options.</p><p>Angpt-TEK signaling is essential for development (<xref ref-type="bibr" rid="bib36">Thomson et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>) and maintenance (<xref ref-type="bibr" rid="bib20">Kim et al., 2017</xref>) of SC, an essential component of the conventional AHO pathway. Dysregulation of Angpt-TEK signaling results in hypomorphic or failed SC formation, elevated IOP and glaucoma in mice and humans. Intriguingly, recent GWAS studies of subjects with ocular hypertension have identified common variants in members of the Angpt-TEK signaling pathway (<xref ref-type="bibr" rid="bib18">Khawaja et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">Gao et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">MacGregor et al., 2018</xref>). These GWAS findings suggest that in addition to the complete loss-of-function variants previously described in PCG, less impactful variants may play a role in more common forms of adult-onset glaucoma. These reports, combined with the strong dose dependent response of SC development and function to TEK signaling observed in the mouse, suggest that the Angpt-TEK signaling axis is a sensitive and important regulator of SC and AHO and may provide a valuable IOP-lowering therapeutic target for treatment of glaucoma patients. Indeed, a recent study has demonstrated the effectiveness of targeting the Angpt-TEK signaling pathway in a mouse model of glaucoma using an antibody which increases the signaling ability of the context-dependent, weak TEK agonist ANGPT2 by clustering it into higher-order multimers (<xref ref-type="bibr" rid="bib20">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Park et al., 2016</xref>). ANGPT2-clustering antibody treatment was found to increase TEK phosphorylation in aged mice and lower IOP in an injury-induced model of ocular hypertension (<xref ref-type="bibr" rid="bib20">Kim et al., 2017</xref>).</p><p>Here, we demonstrate an alternative approach targeting the endothelial phosphatase PTPRB, which acts on TEK (<xref ref-type="bibr" rid="bib34">Souma et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Winderlich et al., 2009</xref>; <xref ref-type="bibr" rid="bib3">Bäumer et al., 2006</xref>) as well as VE-Cadherin, VEGFR2 and FGD5 (<xref ref-type="bibr" rid="bib26">Nawroth et al., 2002</xref>; <xref ref-type="bibr" rid="bib7">Broermann et al., 2011</xref>; <xref ref-type="bibr" rid="bib23">Mellberg et al., 2009</xref>; <xref ref-type="bibr" rid="bib14">Hayashi et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Braun et al., 2019</xref>). Using a genetic approach to PTPRB ablation allowed us to achieve consistent reduction in protein levels, with deletion of a single <italic>Ptprb</italic> allele leading to approximately 50% reduction in protein expression. In <italic>Tek</italic>-WT lung tissue, this was sufficient to cause a marked elevation in TEK phosphorylation. PTPRB inhibition has been previously studied as a potential therapeutic intervention in vascular disease (<xref ref-type="bibr" rid="bib32">Shen et al., 2014</xref>), and the PTPRB inhibitor AKB-9778 is currently undergoing clinical trials for treatment of diabetic macular edema, where it is well-tolerated by patients (<xref ref-type="bibr" rid="bib8">Campochiaro et al., 2016</xref>). While mid-term results for the AKB-9778 TIME-2 trial failed to achieve the primary endpoint in diabetic macular edema, two important observations were reported from this clinical trial: the drug was well tolerated and safe in patients and IOP was lower in the treatment arm (<xref ref-type="bibr" rid="bib1">Aerpio Pharmaceuticals Inc, 2019</xref>).</p><p>We have previously reported that defects in Angpt-TEK signaling cause a range of SC and IOP phenotypes corresponding to the degree of pathway dysfunction, ranging from complete absence of SC (<italic>Tek</italic> knockout or <italic>Angpt1;Angpt2</italic> double knockout mice) to less severely hypomorphic canal morphology (<italic>Tek</italic> haploinsufficency) (<xref ref-type="bibr" rid="bib36">Thomson et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>). Although the phenotype of <italic>Tek</italic> haploinsufficient mice is milder than that observed in PCG patients with heterozygous <italic>TEK</italic> loss-of-function mutations (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>), we selected this model as <italic>Tek</italic> heterozygous mice are viable, fertile and exhibit a consistent SC phenotype without the need for Cre recombinase-mediated gene deletion. Furthermore, this mouse model has many features of glaucoma including ocular hypertension and loss of retinal ganglion cells which more faithfully recapitulate disease seen in patients with common forms of open angle glaucoma then the more severe model of total <italic>Tek</italic> deletion. Consistent with our previous findings, adult <italic>Tek</italic><sup>+/-</sup> mice in this study displayed a hypomorphic SC phenotype due to decreased EC proliferation which was associated with elevated IOP and loss of BRN3B+ retinal ganglion cells. These defects were blunted by developmental <italic>Ptprb</italic> haploinsufficency in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice, likely due to increased basal TEK phosphorylation and resulting EC proliferation in <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> animals. In addition, expression of PROX1, a key marker of mature SC endothelial cells, was dramatically reduced in <italic>Tek</italic><sup>+/-</sup> SCs at P5. Expression was normal in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> eyes, consistent with previous reports from our lab and elsewhere suggesting that Angpt1-TEK signaling may be critical for maintenance of this crucial transcription factor in the SC endothelium (<xref ref-type="bibr" rid="bib27">Park et al., 2014</xref>; <xref ref-type="bibr" rid="bib20">Kim et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Truong et al., 2014</xref>). However, our data do not indicate whether PROX1 expression is directly downstream of TEK activation or is otherwise dependent on a mature SC endothelial phenotype.</p><p>While these results highlight the potential of PTPRB as a therapeutic target for patients with TEK-associated PCG, the recent association of Angpt-TEK variants with ocular hypertension and the findings of Kim et al using an ANGPT2 clustering antibody suggest that this pathway may also provide a valuable therapeutic target for adult patients with primary open angle glaucoma, a significantly larger group then TEK-associated PCG. Future studies using targeted gene deletion or therapies that inhibit PTPRB such as siRNA, antibodies or small molecule inhibitors will provide additional insights and pave the way for translation of these findings into the clinic.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="bottom">Resource</th><th valign="bottom">Designation</th><th valign="bottom">Source or reference</th><th valign="bottom">Identifiers</th><th valign="bottom">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Genetic Reagent (<italic>M. musculus</italic>)</td><td valign="top"><italic>Ptprb</italic><sup>NLS-LacZ</sup></td><td valign="top"><xref ref-type="bibr" rid="bib3">Bäumer et al., 2006</xref></td><td valign="top"/><td valign="top">Maintained on a <break/>mixed background</td></tr><tr><td valign="top">Genetic Reagent (<italic>M. musculus</italic>)</td><td valign="top"><italic>Tek</italic><sup>+/-</sup></td><td valign="top"><xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref></td><td valign="top">Tek<sup>tm1.1Vlcg</sup>; MGI:5544795</td><td valign="top">Maintained on a mixed background</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-PTPRB (Rabbit polyclonal)</td><td valign="top"><xref ref-type="bibr" rid="bib26">Nawroth et al., 2002</xref></td><td valign="top"/><td valign="top">Western blot: 1:2000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-TEK (Rabbit polyclonal)</td><td valign="top">Santa Cruz Biotech</td><td valign="top">sc-324</td><td valign="top">Western blot 1:2500</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-αTubulin (Mouse monoclonal)</td><td valign="top">Santa Cruz Biotech</td><td valign="top">sc-32293</td><td valign="top">Western blot: 1:10,000</td></tr><tr><td valign="top">Antibody</td><td valign="top">4G10 Platinum anti-phosphotyrosine (Mouse monoclonal)</td><td valign="top">Millipore</td><td valign="top">05–1050</td><td valign="top">Western blot: 1:2000</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-CD31 MEC13.3 (Rat monoclonal)</td><td valign="top">BD Biosciences</td><td valign="top">55337</td><td valign="top">IF: 1:100</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-PROX1 (Goat polyclonal)</td><td valign="top">R and D Systems</td><td valign="top">AF2727</td><td valign="top">IF: 1:200</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-Ki-67 (Rabbit monoclonal)</td><td valign="top">ThermoFisher</td><td valign="top">MA5-14520</td><td valign="top">IF: 1:200</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-BRN3b (Goat polyclonal)</td><td valign="top">Santa Cruz Biotech</td><td valign="top">sc-6026</td><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">ImageJ Fiji</td><td valign="top"><xref ref-type="bibr" rid="bib31">Schindelin et al., 2012</xref></td><td valign="top">Version 1.52 p</td><td valign="top">Used for all <break/>image analysis</td></tr><tr><td valign="top">Software, algorithm</td><td valign="top">Graphpad Prism</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">Graphpad.com</ext-link></td><td valign="top">Version 5.0</td><td valign="top">Used for statistical analysis and graph generation</td></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">Adobe Indesign</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.adobe.com/">Adobe.com</ext-link></td><td valign="top">Version 14.01 × 64</td><td valign="top">Used for figure creation</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Study approval</title><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the ARVO guidelines for care and use of vertebrate research subjects in eye research. All animal experiments were approved by the Animal Care Committee at the Center for Comparative Medicine of Northwestern University (Evanston, Illinois, USA).</p></sec><sec id="s4-2"><title>Generation and breeding of <italic>Tek<sup>+/-</sup>;Ptprb<sup>NLS-LacZ/WT</sup></italic>mice</title><p><italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice have been previously described (<xref ref-type="bibr" rid="bib42">Winderlich et al., 2009</xref>; <xref ref-type="bibr" rid="bib3">Bäumer et al., 2006</xref>) and were a generous gift of Dr. Dietmar Vestweber (Max Planck Institute, Münster, Germany). <italic>Tek<sup>+/-</sup></italic> mice were generated by crossing <italic>Tek</italic><sup>COIN</sup> (<xref ref-type="bibr" rid="bib36">Thomson et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Economides et al., 2013</xref>) mice with <italic>Rosa26<sup>rtTA</sup>;</italic>TetOnCre (<xref ref-type="bibr" rid="bib5">Belteki et al., 2005</xref>) as previously described (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>). After undergoing Cre-mediated gene deletion, animals were crossed with WT ICR mice to obtain <italic>Tek</italic><sup>+/-</sup> animals which did not express the TetOnCre or <italic>Rosa26</italic><sup>rtTA</sup> transgenes. Throughout the present study, animals were maintained on a mixed genetic background free of the retina degeneration mutations RD1 and RD8 and allowed unrestricted access to standard rodent chow (Harlan Teklad #7912; Envigo, Indianapolis IN) and water. As animals were maintained on a mixed background, littermate controls were used for all experiments and animals were included in the study on the basis of full litters (i.e. a control from one litter would not be included without their matching mutant littermates). To determine experimental group sizes, data from our previous studies of SC morphology (<xref ref-type="bibr" rid="bib33">Souma et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>) were used to estimate required numbers. Breeding cages were then set up based on these estimates, and all resulting animals were included in the described studies.</p></sec><sec id="s4-3"><title>Western blot</title><p>Lung samples from Tek<sup>+/-</sup>, <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> and Tek<sup>+/-</sup>, <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice with control littermates were homogenized in RIPA buffer (50 mM TRIS, 150 mM NaCl, 1% IGEPAL CA-630, 0.5% Na Deoxycholate, 0.1% SDS, pH 7.5) containing protease and phosphatase inhibitor cocktails (Sigma). Samples were lysed (30 min at 4°C) and centrifuged (10 min at 14,000*g, 4°C) before the supernatant was used for western blot and immunoprecipitation. For western blot, 100 μg lysate was separated on a 4–15% Tris-glycine gel (Bio-Rad) and transferred to PVDF membranes using standard methods. Membranes were then cut horizontally at 75 kDa and blocked in (5% BSA in Tris buffered saline containing 0.05% Tween-20, pH 7.5) before incubating with appropriate primary and HRP-conjugated secondary antibodies (Jackson Immunoresearch). After washing, membranes were incubated in ECL substrate (SuperSignal West Pico PLUS, Thermo Fisher) and imaged on an iBright 1500 digital camera system (Thermo Fisher-Life Technologies). Quantification was performed using ImageJ Fiji software (<xref ref-type="bibr" rid="bib31">Schindelin et al., 2012</xref>). Values obtained from quantifying total TEK or PTPRB were normalized to matching alpha-tubulin bands obtained from the lower (&lt;75 kDA) region of the same membrane. Primary antibodies used: Rabbit anti-TEK (Santa Cruz Biotech #sc-324, 1:2500), mouse anti-alpha tubulin (Santa Cruz Biotech #sc-32293, 1:10,000), rabbit anti-PTPRB (<xref ref-type="bibr" rid="bib26">Nawroth et al., 2002</xref>).</p><p>For Immunoprecipitation assays of TEK phosphorylation, 1 mg of protein lysate was incubated with 1 μg rabbit anti-TEK antibody (C-20, Santa Cruz) before antibody-protein complexes were captured using Protein-A conjugated Dynabeads (Invitrogen). Proteins were then eluted by boiling in 2x Laemmli sample buffer containing 100 mM DTT, loaded on a 4–15% Tris-glycine gel and separated by SDS-PAGE as described above. Phosphorylated tyrosine was detected using mouse anti-phospho-tyrosine antibody (4G10 Platinum, Millipore #05–1050, 1:2000) before membranes were stripped using a commercial stripping solution (Restore, Thermo Fisher # 21059) and re-probed using anti-TEK antibody as described above. Bands were imaged using a ChemiDock imaging system (Bio-Rad) and quantified as above. Relative TEK phosphorylation is reported in the manuscript as a normalized ratio of pTyr:Total TEK signals obtained from the same membrane. All western blot and immunoprecipitation experiments were performed at least twice. Values and statistics reported are derived from the data shown in the manuscript.</p></sec><sec id="s4-4"><title>Schlemm’s canal immunostaining and imaging</title><p>Whole-mount imaging of SC was performed as described previously (<xref ref-type="bibr" rid="bib37">Thomson et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Thomson and Quaggin, 2018</xref>). Briefly, enucleated eye globes were immersion fixed (2% formaldehyde in 0.1M phosphate buffer pH 7.5, 12 hr at 4°C) before the lens and retina were removed and limbal flat mounts were prepared. Tissues were blocked (5% donkey serum, 2.5% bovine serum albumin in Tris buffered saline pH 7.5 containing 0.5% Triton X-100, overnight at 4°C) before incubating in appropriate primary and alexafluor-labled secondary antibodies (Thermo Fisher Scientific, Waltham, MA) diluted in additional blocking buffer. Antibodies used: Rat anti-mouse CD31 (Dilution 1:100. #55337, BD Biosciences, Franklin Lakes New Jersey), Rabbit anti-human Ki-67 (Dilution 1:200. #MA5-14520, ThermoFisher Scientific, Waltham, MA), goat anti-human PROX1 (Dilution 1:200. #AF2727, R and D Systems, Minneapolis, MN). After staining, tissues were washed (Tris buffered saline pH 7.5 containing 0.05% Tween-20) and mounted on microscope slides. Images were captured using a Nikon A1R confocal microscope at the Center for Advanced Microscopy at Northwestern University equipped with a 20x objective with a numerical aperture of 0.75. To measure SC area, 3 10-image Z stacks were captured using a step size of 1.67 μm and a pinhole of 1.2 Airy units at intervals around the circumference of SC. To prevent bias in image location selection, the episclaral vein was used as a landmark for the initial field and subsequent images were taken at 120° intervals. In the manuscript, images of SC are shown as maximum intensity projections of these 10-image Z stacks. Canal area was measured in each 65,536 μm<sup>2</sup> field using Fiji software (<xref ref-type="bibr" rid="bib31">Schindelin et al., 2012</xref>) and an average value was obtained for each eye. Likewise, quantification of Ki-67 and PROX1 expression was performed in three imaging zones from each eye and the results were averaged to obtain the reported value for the animal. eight image confocal Z stacks were obtained with a step size of 1 μm and pinhole of 1.2. Ki-67 positive nuclei were counted manually using ImageJ Fiji software. PROX1 expression was reported as mean background-subtracted fluorescence per μm<sup>2</sup> CD31+ SC area as measured using ImageJ Fiji software. Quantification of convolutions and focal defects was performed from stitched images of the full SC circumference obtained using the objective described above with the pinhole set to 150 μm.</p></sec><sec id="s4-5"><title>Intraocular pressure measurement</title><p>IOP measurements were obtained from awake mice using a Tonolab rebound tonometer (iCare) as previously described (<xref ref-type="bibr" rid="bib36">Thomson et al., 2014</xref>; <xref ref-type="bibr" rid="bib15">John et al., 1997</xref>). Animals were restrained in a soft plastic cone, and average IOPs were recorded from 3 sets of 6 recordings performed by a blinded technician. Finding no difference between left and right eyes, we have reported all IOP measurements as single averaged values for each animal.</p></sec><sec id="s4-6"><title>Retinal ganglion cell quantification</title><p>Enucleated eyes from <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice with littermate <italic>Tek</italic><sup>+/-</sup>, <italic>Ptprb</italic><sup>NLS-LacZ/WT</sup>, and WT controls were collected at 19 weeks and fixed as above. Retinas were collected before blocking and staining as above. Antibodies used: Goat anti BRN3 (Dilution: 1:1000. Santa Cruz Biotechnology, sc-6026). Retinas were imaged in a standardized pattern as flat mounts using a Nikon A1R microscope as described above and BRN3+ ganglion cells were quantified by a blinded student.</p></sec><sec id="s4-7"><title>Statistical analysis</title><p>Statistical analysis was performed using Prism 5.0 software (Graphpad, La Jolla CA USA). Two-tailed Student’s t-test or ANOVA followed by use of Bonferroni’s method for multiple comparisons were used for statistical significance testing as appropriate. Throughout the text, values are reported as means ± standard error (SEM). In figures, plotted data points represent average values from individual animals with horizontal lines indicating the group mean. p-values&lt;0.05 were considered significant and are indicated in figures using the following notation: *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are grateful to Megan Kelly and Veronica Ramirez for technical assistance. This study was funded by NIH R01 HL124120, R01 EY025799 (to SEQ). Imaging was performed at the Northwestern University Center for Advanced Microscopy supported by NCI CCSG P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center. We also acknowledge support from the George M O’Brien Kidney Core Grant P30 DK114857.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>was employed by Eli Lilly and Company during the time of study completion and manuscript preparation</p></fn><fn fn-type="COI-statement" id="conf3"><p>is a scientific advisory board member of Aerpio Pharmaceuticals</p></fn><fn fn-type="COI-statement" id="conf4"><p>has applied for patents related to therapeutic targeting of the ANGPT-TEK pathway in ocular hypertension and glaucoma and receives research support, owns stock in and is a director of Mannin Research</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the ARVO guidelines for care and use of vertebrate research subjects in eye research. All animal experiments were approved by the Animal Care Committee at the Center for Comparative Medicine of Northwestern University (Evanston, Illinois, USA) under animal protocols IS00002777, IS00006571 and IS00003091.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-48474-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data described have been included in the manuscript. No data sets were generated during the course of this study.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Aerpio Pharmaceuticals Inc</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Aerpio pharmaceuticals announces results from time-2b study of akb-9778 in diabetic retinopathy [Press release]</article-title><ext-link ext-link-type="uri" xlink:href="http://ir.aerpio.com/phoenix.zhtml?c=254540&amp;p=irol-newsArticle&amp;ID=2391547">http://ir.aerpio.com/phoenix.zhtml?c=254540&amp;p=irol-newsArticle&amp;ID=2391547</ext-link><date-in-citation iso-8601-date="2019-03-18">March 18, 2019</date-in-citation></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspelund</surname> <given-names>A</given-names></name><name><surname>Tammela</surname> <given-names>T</given-names></name><name><surname>Antila</surname> <given-names>S</given-names></name><name><surname>Nurmi</surname> <given-names>H</given-names></name><name><surname>Leppänen</surname> <given-names>VM</given-names></name><name><surname>Zarkada</surname> <given-names>G</given-names></name><name><surname>Stanczuk</surname> <given-names>L</given-names></name><name><surname>Francois</surname> <given-names>M</given-names></name><name><surname>Mäkinen</surname> <given-names>T</given-names></name><name><surname>Saharinen</surname> <given-names>P</given-names></name><name><surname>Immonen</surname> <given-names>I</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>3975</fpage><lpage>3986</lpage><pub-id pub-id-type="doi">10.1172/JCI75395</pub-id><pub-id pub-id-type="pmid">25061878</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bäumer</surname> <given-names>S</given-names></name><name><surname>Keller</surname> <given-names>L</given-names></name><name><surname>Holtmann</surname> <given-names>A</given-names></name><name><surname>Funke</surname> <given-names>R</given-names></name><name><surname>August</surname> <given-names>B</given-names></name><name><surname>Gamp</surname> <given-names>A</given-names></name><name><surname>Wolburg</surname> <given-names>H</given-names></name><name><surname>Wolburg-Buchholz</surname> <given-names>K</given-names></name><name><surname>Deutsch</surname> <given-names>U</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development</article-title><source>Blood</source><volume>107</volume><fpage>4754</fpage><lpage>4762</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-01-0141</pub-id><pub-id pub-id-type="pmid">16514057</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1961">1961</year><article-title>Tonography in the diagnosis of simple (open angle) glaucoma</article-title><source>Transactions - American Academy of Ophthalmology and Otolaryngology</source><volume>65</volume><fpage>156</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">13688434</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belteki</surname> <given-names>G</given-names></name><name><surname>Haigh</surname> <given-names>J</given-names></name><name><surname>Kabacs</surname> <given-names>N</given-names></name><name><surname>Haigh</surname> <given-names>K</given-names></name><name><surname>Sison</surname> <given-names>K</given-names></name><name><surname>Costantini</surname> <given-names>F</given-names></name><name><surname>Whitsett</surname> <given-names>J</given-names></name><name><surname>Quaggin</surname> <given-names>SE</given-names></name><name><surname>Nagy</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction</article-title><source>Nucleic Acids Research</source><volume>33</volume><elocation-id>e51</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gni051</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname> <given-names>LJ</given-names></name><name><surname>Zinnhardt</surname> <given-names>M</given-names></name><name><surname>Vockel</surname> <given-names>M</given-names></name><name><surname>Drexler</surname> <given-names>HC</given-names></name><name><surname>Peters</surname> <given-names>K</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>VE-PTP inhibition stabilizes endothelial junctions by activating FGD5</article-title><source>EMBO Reports</source><volume>20</volume><elocation-id>e47046</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201847046</pub-id><pub-id pub-id-type="pmid">31267715</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broermann</surname> <given-names>A</given-names></name><name><surname>Winderlich</surname> <given-names>M</given-names></name><name><surname>Block</surname> <given-names>H</given-names></name><name><surname>Frye</surname> <given-names>M</given-names></name><name><surname>Rossaint</surname> <given-names>J</given-names></name><name><surname>Zarbock</surname> <given-names>A</given-names></name><name><surname>Cagna</surname> <given-names>G</given-names></name><name><surname>Linnepe</surname> <given-names>R</given-names></name><name><surname>Schulte</surname> <given-names>D</given-names></name><name><surname>Nottebaum</surname> <given-names>AF</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>2393</fpage><lpage>2401</lpage><pub-id pub-id-type="doi">10.1084/jem.20110525</pub-id><pub-id pub-id-type="pmid">22025303</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname> <given-names>PA</given-names></name><name><surname>Khanani</surname> <given-names>A</given-names></name><name><surname>Singer</surname> <given-names>M</given-names></name><name><surname>Patel</surname> <given-names>S</given-names></name><name><surname>Boyer</surname> <given-names>D</given-names></name><name><surname>Dugel</surname> <given-names>P</given-names></name><name><surname>Kherani</surname> <given-names>S</given-names></name><name><surname>Withers</surname> <given-names>B</given-names></name><name><surname>Gambino</surname> <given-names>L</given-names></name><name><surname>Peters</surname> <given-names>K</given-names></name><name><surname>Brigell</surname> <given-names>M</given-names></name><collab>TIME-2 Study Group</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression</article-title><source>Ophthalmology</source><volume>123</volume><fpage>1722</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2016.04.025</pub-id><pub-id pub-id-type="pmid">27236272</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carota</surname> <given-names>IA</given-names></name><name><surname>Kenig-Kozlovsky</surname> <given-names>Y</given-names></name><name><surname>Onay</surname> <given-names>T</given-names></name><name><surname>Scott</surname> <given-names>R</given-names></name><name><surname>Thomson</surname> <given-names>BR</given-names></name><name><surname>Souma</surname> <given-names>T</given-names></name><name><surname>Bartlett</surname> <given-names>CS</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Procissi</surname> <given-names>D</given-names></name><name><surname>Ramirez</surname> <given-names>V</given-names></name><name><surname>Yamaguchi</surname> <given-names>S</given-names></name><name><surname>Tarjus</surname> <given-names>A</given-names></name><name><surname>Tanna</surname> <given-names>CE</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Eremina</surname> <given-names>V</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name><name><surname>Oladipupo</surname> <given-names>SS</given-names></name><name><surname>Breyer</surname> <given-names>MD</given-names></name><name><surname>Quaggin</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Targeting VE-PTP phosphatase protects the kidney from diabetic injury</article-title><source>The Journal of Experimental Medicine</source><volume>216</volume><fpage>936</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1084/jem.20180009</pub-id><pub-id pub-id-type="pmid">30886059</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname> <given-names>AL</given-names></name><name><surname>Miglior</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Risk factors for Glaucoma onset and progression</article-title><source>Survey of Ophthalmology</source><volume>53 Suppl1</volume><fpage>S3</fpage><lpage>S10</lpage><pub-id pub-id-type="doi">10.1016/j.survophthal.2008.08.006</pub-id><pub-id pub-id-type="pmid">19038621</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Economides</surname> <given-names>AN</given-names></name><name><surname>Frendewey</surname> <given-names>D</given-names></name><name><surname>Yang</surname> <given-names>P</given-names></name><name><surname>Dominguez</surname> <given-names>MG</given-names></name><name><surname>Dore</surname> <given-names>AT</given-names></name><name><surname>Lobov</surname> <given-names>IB</given-names></name><name><surname>Persaud</surname> <given-names>T</given-names></name><name><surname>Rojas</surname> <given-names>J</given-names></name><name><surname>McClain</surname> <given-names>J</given-names></name><name><surname>Lengyel</surname> <given-names>P</given-names></name><name><surname>Droguett</surname> <given-names>G</given-names></name><name><surname>Chernomorsky</surname> <given-names>R</given-names></name><name><surname>Stevens</surname> <given-names>S</given-names></name><name><surname>Auerbach</surname> <given-names>W</given-names></name><name><surname>Dechiara</surname> <given-names>TM</given-names></name><name><surname>Pouyemirou</surname> <given-names>W</given-names></name><name><surname>Cruz</surname> <given-names>JM</given-names></name><name><surname>Feeley</surname> <given-names>K</given-names></name><name><surname>Mellis</surname> <given-names>IA</given-names></name><name><surname>Yasenchack</surname> <given-names>J</given-names></name><name><surname>Hatsell</surname> <given-names>SJ</given-names></name><name><surname>Xie</surname> <given-names>L</given-names></name><name><surname>Latres</surname> <given-names>E</given-names></name><name><surname>Huang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Pefanis</surname> <given-names>E</given-names></name><name><surname>Skokos</surname> <given-names>D</given-names></name><name><surname>Deckelbaum</surname> <given-names>RA</given-names></name><name><surname>Croll</surname> <given-names>SD</given-names></name><name><surname>Davis</surname> <given-names>S</given-names></name><name><surname>Valenzuela</surname> <given-names>DM</given-names></name><name><surname>Gale</surname> <given-names>NW</given-names></name><name><surname>Murphy</surname> <given-names>AJ</given-names></name><name><surname>Yancopoulos</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Conditionals by inversion provide a universal method for the generation of conditional alleles</article-title><source>PNAS</source><volume>110</volume><fpage>E3179</fpage><lpage>E3188</lpage><pub-id pub-id-type="doi">10.1073/pnas.1217812110</pub-id><pub-id pub-id-type="pmid">23918385</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fachinger</surname> <given-names>G</given-names></name><name><surname>Deutsch</surname> <given-names>U</given-names></name><name><surname>Risau</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2</article-title><source>Oncogene</source><volume>18</volume><fpage>5948</fpage><lpage>5953</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202992</pub-id><pub-id pub-id-type="pmid">10557082</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>XR</given-names></name><name><surname>Huang</surname> <given-names>H</given-names></name><name><surname>Nannini</surname> <given-names>DR</given-names></name><name><surname>Fan</surname> <given-names>F</given-names></name><name><surname>Kim</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genome-wide association analyses identify new loci influencing intraocular pressure</article-title><source>Human Molecular Genetics</source><volume>27</volume><fpage>2205</fpage><lpage>2213</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy111</pub-id><pub-id pub-id-type="pmid">29617998</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname> <given-names>M</given-names></name><name><surname>Majumdar</surname> <given-names>A</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Adler</surname> <given-names>J</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name><name><surname>Vertuani</surname> <given-names>S</given-names></name><name><surname>Hellberg</surname> <given-names>C</given-names></name><name><surname>Mellberg</surname> <given-names>S</given-names></name><name><surname>Koch</surname> <given-names>S</given-names></name><name><surname>Dimberg</surname> <given-names>A</given-names></name><name><surname>Koh</surname> <given-names>GY</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name><name><surname>Belting</surname> <given-names>HG</given-names></name><name><surname>Affolter</surname> <given-names>M</given-names></name><name><surname>Thurston</surname> <given-names>G</given-names></name><name><surname>Holmgren</surname> <given-names>L</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>1672</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2683</pub-id><pub-id pub-id-type="pmid">23575676</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname> <given-names>SW</given-names></name><name><surname>Hagaman</surname> <given-names>JR</given-names></name><name><surname>MacTaggart</surname> <given-names>TE</given-names></name><name><surname>Peng</surname> <given-names>L</given-names></name><name><surname>Smithes</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Intraocular pressure in inbred mouse strains</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>38</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">9008647</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>M</given-names></name><name><surname>McLaren</surname> <given-names>JW</given-names></name><name><surname>Overby</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Unconventional aqueous humor outflow: a review</article-title><source>Experimental Eye Research</source><volume>158</volume><fpage>94</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2016.01.017</pub-id><pub-id pub-id-type="pmid">26850315</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabra</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Rathi</surname> <given-names>S</given-names></name><name><surname>Mandal</surname> <given-names>AK</given-names></name><name><surname>Senthil</surname> <given-names>S</given-names></name><name><surname>Pyatla</surname> <given-names>G</given-names></name><name><surname>Ramappa</surname> <given-names>M</given-names></name><name><surname>Banerjee</surname> <given-names>S</given-names></name><name><surname>Shekhar</surname> <given-names>K</given-names></name><name><surname>Marmamula</surname> <given-names>S</given-names></name><name><surname>Mettla</surname> <given-names>AL</given-names></name><name><surname>Kaur</surname> <given-names>I</given-names></name><name><surname>Khanna</surname> <given-names>RC</given-names></name><name><surname>Khanna</surname> <given-names>H</given-names></name><name><surname>Chakrabarti</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Angiopoietin receptor TEK interacts with CYP1B1 in primary congenital Glaucoma</article-title><source>Human Genetics</source><volume>136</volume><fpage>941</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1007/s00439-017-1823-6</pub-id><pub-id pub-id-type="pmid">28620713</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khawaja</surname> <given-names>AP</given-names></name><name><surname>Cooke Bailey</surname> <given-names>JN</given-names></name><name><surname>Wareham</surname> <given-names>NJ</given-names></name><name><surname>Scott</surname> <given-names>RA</given-names></name><name><surname>Simcoe</surname> <given-names>M</given-names></name><name><surname>Igo</surname> <given-names>RP</given-names></name><name><surname>Song</surname> <given-names>YE</given-names></name><name><surname>Wojciechowski</surname> <given-names>R</given-names></name><name><surname>Cheng</surname> <given-names>CY</given-names></name><name><surname>Khaw</surname> <given-names>PT</given-names></name><name><surname>Pasquale</surname> <given-names>LR</given-names></name><name><surname>Haines</surname> <given-names>JL</given-names></name><name><surname>Foster</surname> <given-names>PJ</given-names></name><name><surname>Wiggs</surname> <given-names>JL</given-names></name><name><surname>Hammond</surname> <given-names>CJ</given-names></name><name><surname>Hysi</surname> <given-names>PG</given-names></name><collab>UK Biobank Eye and Vision Consortium, NEIGHBORHOOD Consortium</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle Glaucoma</article-title><source>Nature Genetics</source><volume>50</volume><fpage>778</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0126-8</pub-id><pub-id pub-id-type="pmid">29785010</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>KT</given-names></name><name><surname>Choi</surname> <given-names>HH</given-names></name><name><surname>Steinmetz</surname> <given-names>MO</given-names></name><name><surname>Maco</surname> <given-names>B</given-names></name><name><surname>Kammerer</surname> <given-names>RA</given-names></name><name><surname>Ahn</surname> <given-names>SY</given-names></name><name><surname>Kim</surname> <given-names>HZ</given-names></name><name><surname>Lee</surname> <given-names>GM</given-names></name><name><surname>Koh</surname> <given-names>GY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>20126</fpage><lpage>20131</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500292200</pub-id><pub-id pub-id-type="pmid">15769741</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>J</given-names></name><name><surname>Park</surname> <given-names>DY</given-names></name><name><surname>Bae</surname> <given-names>H</given-names></name><name><surname>Park</surname> <given-names>DY</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>CK</given-names></name><name><surname>Song</surname> <given-names>S</given-names></name><name><surname>Chung</surname> <given-names>TY</given-names></name><name><surname>Lim</surname> <given-names>DH</given-names></name><name><surname>Kubota</surname> <given-names>Y</given-names></name><name><surname>Hong</surname> <given-names>YK</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Augustin</surname> <given-names>HG</given-names></name><name><surname>Oliver</surname> <given-names>G</given-names></name><name><surname>Koh</surname> <given-names>GY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Impaired angiopoietin/Tie2 signaling compromises schlemm's canal integrity and induces glaucoma</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>3877</fpage><lpage>3896</lpage><pub-id pub-id-type="doi">10.1172/JCI94668</pub-id><pub-id pub-id-type="pmid">28920924</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kizhatil</surname> <given-names>K</given-names></name><name><surname>Ryan</surname> <given-names>M</given-names></name><name><surname>Marchant</surname> <given-names>JK</given-names></name><name><surname>Henrich</surname> <given-names>S</given-names></name><name><surname>John</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Schlemm's canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process</article-title><source>PLOS Biology</source><volume>12</volume><elocation-id>e1001912</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1001912</pub-id><pub-id pub-id-type="pmid">25051267</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacGregor</surname> <given-names>S</given-names></name><name><surname>Ong</surname> <given-names>JS</given-names></name><name><surname>An</surname> <given-names>J</given-names></name><name><surname>Han</surname> <given-names>X</given-names></name><name><surname>Zhou</surname> <given-names>T</given-names></name><name><surname>Siggs</surname> <given-names>OM</given-names></name><name><surname>Law</surname> <given-names>MH</given-names></name><name><surname>Souzeau</surname> <given-names>E</given-names></name><name><surname>Sharma</surname> <given-names>S</given-names></name><name><surname>Lynn</surname> <given-names>DJ</given-names></name><name><surname>Beesley</surname> <given-names>J</given-names></name><name><surname>Sheldrick</surname> <given-names>B</given-names></name><name><surname>Mills</surname> <given-names>RA</given-names></name><name><surname>Landers</surname> <given-names>J</given-names></name><name><surname>Ruddle</surname> <given-names>JB</given-names></name><name><surname>Graham</surname> <given-names>SL</given-names></name><name><surname>Healey</surname> <given-names>PR</given-names></name><name><surname>White</surname> <given-names>AJR</given-names></name><name><surname>Casson</surname> <given-names>RJ</given-names></name><name><surname>Best</surname> <given-names>S</given-names></name><name><surname>Grigg</surname> <given-names>JR</given-names></name><name><surname>Goldberg</surname> <given-names>I</given-names></name><name><surname>Powell</surname> <given-names>JE</given-names></name><name><surname>Whiteman</surname> <given-names>DC</given-names></name><name><surname>Radford-Smith</surname> <given-names>GL</given-names></name><name><surname>Martin</surname> <given-names>NG</given-names></name><name><surname>Montgomery</surname> <given-names>GW</given-names></name><name><surname>Burdon</surname> <given-names>KP</given-names></name><name><surname>Mackey</surname> <given-names>DA</given-names></name><name><surname>Gharahkhani</surname> <given-names>P</given-names></name><name><surname>Craig</surname> <given-names>JE</given-names></name><name><surname>Hewitt</surname> <given-names>AW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genome-wide association study of intraocular pressure uncovers new pathways to Glaucoma</article-title><source>Nature Genetics</source><volume>50</volume><fpage>1067</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0176-y</pub-id><pub-id pub-id-type="pmid">30054594</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellberg</surname> <given-names>S</given-names></name><name><surname>Dimberg</surname> <given-names>A</given-names></name><name><surname>Bahram</surname> <given-names>F</given-names></name><name><surname>Hayashi</surname> <given-names>M</given-names></name><name><surname>Rennel</surname> <given-names>E</given-names></name><name><surname>Ameur</surname> <given-names>A</given-names></name><name><surname>Westholm</surname> <given-names>JO</given-names></name><name><surname>Larsson</surname> <given-names>E</given-names></name><name><surname>Lindahl</surname> <given-names>P</given-names></name><name><surname>Cross</surname> <given-names>MJ</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis</article-title><source>The FASEB Journal</source><volume>23</volume><fpage>1490</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1096/fj.08-123810</pub-id><pub-id pub-id-type="pmid">19136612</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname> <given-names>JC</given-names></name><name><surname>Clark</surname> <given-names>AF</given-names></name><name><surname>Pang</surname> <given-names>I-H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Assessment of aqueous humor dynamics in the mouse by a novel method of Constant-Flow infusion</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>52</volume><fpage>685</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-6069</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname> <given-names>JC</given-names></name><name><surname>Phan</surname> <given-names>TN</given-names></name><name><surname>Pang</surname> <given-names>I-H</given-names></name><name><surname>Clark</surname> <given-names>AF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Strain and age effects on aqueous humor dynamics in the mouse</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>56</volume><fpage>5764</fpage><lpage>5776</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-16720</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawroth</surname> <given-names>R</given-names></name><name><surname>Poell</surname> <given-names>G</given-names></name><name><surname>Ranft</surname> <given-names>A</given-names></name><name><surname>Kloep</surname> <given-names>S</given-names></name><name><surname>Samulowitz</surname> <given-names>U</given-names></name><name><surname>Fachinger</surname> <given-names>G</given-names></name><name><surname>Golding</surname> <given-names>M</given-names></name><name><surname>Shima</surname> <given-names>DT</given-names></name><name><surname>Deutsch</surname> <given-names>U</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts</article-title><source>The EMBO Journal</source><volume>21</volume><fpage>4885</fpage><lpage>4895</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdf497</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>DY</given-names></name><name><surname>Lee</surname> <given-names>J</given-names></name><name><surname>Park</surname> <given-names>I</given-names></name><name><surname>Choi</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Song</surname> <given-names>S</given-names></name><name><surname>Hwang</surname> <given-names>Y</given-names></name><name><surname>Hong</surname> <given-names>KY</given-names></name><name><surname>Nakaoka</surname> <given-names>Y</given-names></name><name><surname>Makinen</surname> <given-names>T</given-names></name><name><surname>Kim</surname> <given-names>P</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name><name><surname>Hong</surname> <given-names>YK</given-names></name><name><surname>Koh</surname> <given-names>GY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lymphatic regulator PROX1 determines schlemm's canal integrity and identity</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>3960</fpage><lpage>3974</lpage><pub-id pub-id-type="doi">10.1172/JCI75392</pub-id><pub-id pub-id-type="pmid">25061877</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>JS</given-names></name><name><surname>Kim</surname> <given-names>IK</given-names></name><name><surname>Han</surname> <given-names>S</given-names></name><name><surname>Park</surname> <given-names>I</given-names></name><name><surname>Kim</surname> <given-names>C</given-names></name><name><surname>Bae</surname> <given-names>J</given-names></name><name><surname>Oh</surname> <given-names>SJ</given-names></name><name><surname>Lee</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Woo</surname> <given-names>DC</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Augustin</surname> <given-names>HG</given-names></name><name><surname>Kim</surname> <given-names>I</given-names></name><name><surname>Lee</surname> <given-names>D</given-names></name><name><surname>Koh</surname> <given-names>GY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment</article-title><source>Cancer Cell</source><volume>30</volume><fpage>953</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.10.018</pub-id><pub-id pub-id-type="pmid">27960088</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plenge</surname> <given-names>RM</given-names></name><name><surname>Scolnick</surname> <given-names>EM</given-names></name><name><surname>Altshuler</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Validating therapeutic targets through human genetics</article-title><source>Nature Reviews Drug Discovery</source><volume>12</volume><fpage>581</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1038/nrd4051</pub-id><pub-id pub-id-type="pmid">23868113</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saharinen</surname> <given-names>P</given-names></name><name><surname>Eklund</surname> <given-names>L</given-names></name><name><surname>Alitalo</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Therapeutic targeting of the angiopoietin-TIE pathway</article-title><source>Nature Reviews Drug Discovery</source><volume>16</volume><fpage>635</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1038/nrd.2016.278</pub-id><pub-id pub-id-type="pmid">28529319</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>J-Y</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>J</given-names></name><name><surname>Frye</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>BL</given-names></name><name><surname>Reinardy</surname> <given-names>JL</given-names></name><name><surname>McClung</surname> <given-names>JM</given-names></name><name><surname>Ding</surname> <given-names>K</given-names></name><name><surname>Kojima</surname> <given-names>M</given-names></name><name><surname>Xia</surname> <given-names>H</given-names></name><name><surname>Seidel</surname> <given-names>C</given-names></name><name><surname>Lima e Silva</surname> <given-names>R</given-names></name><name><surname>Dong</surname> <given-names>A</given-names></name><name><surname>Hackett</surname> <given-names>SF</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Howard</surname> <given-names>BW</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name><name><surname>Kontos</surname> <given-names>CD</given-names></name><name><surname>Peters</surname> <given-names>KG</given-names></name><name><surname>Campochiaro</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>4564</fpage><lpage>4576</lpage><pub-id pub-id-type="doi">10.1172/JCI74527</pub-id><pub-id pub-id-type="pmid">25180601</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souma</surname> <given-names>T</given-names></name><name><surname>Tompson</surname> <given-names>SW</given-names></name><name><surname>Thomson</surname> <given-names>BR</given-names></name><name><surname>Siggs</surname> <given-names>OM</given-names></name><name><surname>Kizhatil</surname> <given-names>K</given-names></name><name><surname>Yamaguchi</surname> <given-names>S</given-names></name><name><surname>Feng</surname> <given-names>L</given-names></name><name><surname>Limviphuvadh</surname> <given-names>V</given-names></name><name><surname>Whisenhunt</surname> <given-names>KN</given-names></name><name><surname>Maurer-Stroh</surname> <given-names>S</given-names></name><name><surname>Yanovitch</surname> <given-names>TL</given-names></name><name><surname>Kalaydjieva</surname> <given-names>L</given-names></name><name><surname>Azmanov</surname> <given-names>DN</given-names></name><name><surname>Finzi</surname> <given-names>S</given-names></name><name><surname>Mauri</surname> <given-names>L</given-names></name><name><surname>Javadiyan</surname> <given-names>S</given-names></name><name><surname>Souzeau</surname> <given-names>E</given-names></name><name><surname>Zhou</surname> <given-names>T</given-names></name><name><surname>Hewitt</surname> <given-names>AW</given-names></name><name><surname>Kloss</surname> <given-names>B</given-names></name><name><surname>Burdon</surname> <given-names>KP</given-names></name><name><surname>Mackey</surname> <given-names>DA</given-names></name><name><surname>Allen</surname> <given-names>KF</given-names></name><name><surname>Ruddle</surname> <given-names>JB</given-names></name><name><surname>Lim</surname> <given-names>SH</given-names></name><name><surname>Rozen</surname> <given-names>S</given-names></name><name><surname>Tran-Viet</surname> <given-names>KN</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>John</surname> <given-names>S</given-names></name><name><surname>Wiggs</surname> <given-names>JL</given-names></name><name><surname>Pasutto</surname> <given-names>F</given-names></name><name><surname>Craig</surname> <given-names>JE</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Quaggin</surname> <given-names>SE</given-names></name><name><surname>Young</surname> <given-names>TL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Angiopoietin receptor TEK mutations underlie primary congenital Glaucoma with variable expressivity</article-title><source>Journal of Clinical Investigation</source><volume>126</volume><fpage>2575</fpage><lpage>2587</lpage><pub-id pub-id-type="doi">10.1172/JCI85830</pub-id><pub-id pub-id-type="pmid">27270174</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souma</surname> <given-names>T</given-names></name><name><surname>Thomson</surname> <given-names>BR</given-names></name><name><surname>Heinen</surname> <given-names>S</given-names></name><name><surname>Carota</surname> <given-names>IA</given-names></name><name><surname>Yamaguchi</surname> <given-names>S</given-names></name><name><surname>Onay</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Ghosh</surname> <given-names>AK</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Eremina</surname> <given-names>V</given-names></name><name><surname>Hong</surname> <given-names>YK</given-names></name><name><surname>Economides</surname> <given-names>AN</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name><name><surname>Peters</surname> <given-names>KG</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Quaggin</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP</article-title><source>PNAS</source><volume>115</volume><fpage>1298</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1073/pnas.1714446115</pub-id><pub-id pub-id-type="pmid">29358379</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanna</surname> <given-names>AP</given-names></name><name><surname>Johnson</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rho kinase inhibitors as a novel treatment for Glaucoma and ocular hypertension</article-title><source>Ophthalmology</source><volume>125</volume><fpage>1741</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2018.04.040</pub-id><pub-id pub-id-type="pmid">30007591</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname> <given-names>BR</given-names></name><name><surname>Heinen</surname> <given-names>S</given-names></name><name><surname>Jeansson</surname> <given-names>M</given-names></name><name><surname>Ghosh</surname> <given-names>AK</given-names></name><name><surname>Fatima</surname> <given-names>A</given-names></name><name><surname>Sung</surname> <given-names>HK</given-names></name><name><surname>Onay</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Yamaguchi</surname> <given-names>S</given-names></name><name><surname>Economides</surname> <given-names>AN</given-names></name><name><surname>Flenniken</surname> <given-names>A</given-names></name><name><surname>Gale</surname> <given-names>NW</given-names></name><name><surname>Hong</surname> <given-names>YK</given-names></name><name><surname>Fawzi</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Kume</surname> <given-names>T</given-names></name><name><surname>Quaggin</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A lymphatic defect causes ocular hypertension and Glaucoma in mice</article-title><source>Journal of Clinical Investigation</source><volume>124</volume><fpage>4320</fpage><lpage>4324</lpage><pub-id pub-id-type="doi">10.1172/JCI77162</pub-id><pub-id pub-id-type="pmid">25202984</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname> <given-names>BR</given-names></name><name><surname>Souma</surname> <given-names>T</given-names></name><name><surname>Tompson</surname> <given-names>SW</given-names></name><name><surname>Onay</surname> <given-names>T</given-names></name><name><surname>Kizhatil</surname> <given-names>K</given-names></name><name><surname>Siggs</surname> <given-names>OM</given-names></name><name><surname>Feng</surname> <given-names>L</given-names></name><name><surname>Whisenhunt</surname> <given-names>KN</given-names></name><name><surname>Yanovitch</surname> <given-names>TL</given-names></name><name><surname>Kalaydjieva</surname> <given-names>L</given-names></name><name><surname>Azmanov</surname> <given-names>DN</given-names></name><name><surname>Finzi</surname> <given-names>S</given-names></name><name><surname>Tanna</surname> <given-names>CE</given-names></name><name><surname>Hewitt</surname> <given-names>AW</given-names></name><name><surname>Mackey</surname> <given-names>DA</given-names></name><name><surname>Bradfield</surname> <given-names>YS</given-names></name><name><surname>Souzeau</surname> <given-names>E</given-names></name><name><surname>Javadiyan</surname> <given-names>S</given-names></name><name><surname>Wiggs</surname> <given-names>JL</given-names></name><name><surname>Pasutto</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>John</surname> <given-names>SW</given-names></name><name><surname>Craig</surname> <given-names>JE</given-names></name><name><surname>Jin</surname> <given-names>J</given-names></name><name><surname>Young</surname> <given-names>TL</given-names></name><name><surname>Quaggin</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Angiopoietin-1 is required for Schlemm's canal development in mice and humans</article-title><source>Journal of Clinical Investigation</source><volume>127</volume><fpage>4421</fpage><lpage>4436</lpage><pub-id pub-id-type="doi">10.1172/JCI95545</pub-id><pub-id pub-id-type="pmid">29106382</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Thomson</surname> <given-names>BR</given-names></name><name><surname>Quaggin</surname> <given-names>SE</given-names></name></person-group><year iso-8601-date="2018">2018</year><chapter-title>Morphological Analysis of Schlemm’s Canal in Mice</chapter-title><person-group person-group-type="editor"><name><surname>Oliver</surname> <given-names>G</given-names></name><name><surname>Kahn</surname> <given-names>M. L</given-names></name></person-group><source>Lymphangiogenesis: Methods and Protocols</source><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-8712-2_10</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toris</surname> <given-names>CB</given-names></name><name><surname>Yablonski</surname> <given-names>ME</given-names></name><name><surname>Wang</surname> <given-names>Y-L</given-names></name><name><surname>Camras</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Aqueous humor dynamics in the aging human eye</article-title><source>American Journal of Ophthalmology</source><volume>127</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/S0002-9394(98)00436-X</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toris</surname> <given-names>CB</given-names></name><name><surname>Zhan</surname> <given-names>GL</given-names></name><name><surname>Wang</surname> <given-names>YL</given-names></name><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>McLaughlin</surname> <given-names>MA</given-names></name><name><surname>Camras</surname> <given-names>CB</given-names></name><name><surname>Yablonski</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Aqueous humor dynamics in monkeys with laser-induced Glaucoma</article-title><source>Journal of Ocular Pharmacology and Therapeutics</source><volume>16</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1089/jop.2000.16.19</pub-id><pub-id pub-id-type="pmid">10673127</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truong</surname> <given-names>TN</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Hong</surname> <given-names>YK</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Novel characterization and live imaging of schlemm's canal expressing Prox-1</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e98245</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0098245</pub-id><pub-id pub-id-type="pmid">24827370</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winderlich</surname> <given-names>M</given-names></name><name><surname>Keller</surname> <given-names>L</given-names></name><name><surname>Cagna</surname> <given-names>G</given-names></name><name><surname>Broermann</surname> <given-names>A</given-names></name><name><surname>Kamenyeva</surname> <given-names>O</given-names></name><name><surname>Kiefer</surname> <given-names>F</given-names></name><name><surname>Deutsch</surname> <given-names>U</given-names></name><name><surname>Nottebaum</surname> <given-names>AF</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>VE-PTP controls blood vessel development by balancing Tie-2 activity</article-title><source>The Journal of Cell Biology</source><volume>185</volume><fpage>657</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1083/jcb.200811159</pub-id><pub-id pub-id-type="pmid">19451274</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48474.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Smith</surname><given-names>Lois</given-names></name><role>Reviewing Editor</role><aff><institution>Boston Children's Hospital, Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>Thank you for submitting your article &quot;Targeting the phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The authors present the clinical significance of their work up-front: glaucoma is a major cause of blindness worldwide and elevated intraocular pressure (IOP) from decreased aqueous humor outflow via inadequate Schlemm's canal (SC) integrity is a major risk factor for this event. Thomson et al. simply and elegantly demonstrate that haploinsufficiency of VEPTP results in upregulation of Tie2 signaling in vivo and rescues SC agenesis resulting from Tie2 haploinsufficiency. They further demonstrate that compound heterozygosity of VEPTP/<italic>Tek</italic> rescues elevated the IOP and retinal ganglion cell loss observed in <italic>Tek<sup>+/-</sup></italic> mice. The authors acknowledge the extensive prior work performed by their group and others in this area. The current work adds to this literature by confirming the gene dosage effect of <italic>Tek</italic> and <italic>Ptprb</italic> in maintenance of Schlemm's canal and supports the further development of VEPTP inhibitors in the treatment of elevated IOP. The experimental approach is straightforward and logical. Figures are easy to interpret, and the conclusions are well-supported.</p><p>Essential revisions:</p><p>1) Introduction/Discussion: Clearly state that studied phenotypes are developmental rather than acquired. Alternatively, consider adding IOP studies with VE-PTP inhibitor in the <italic>Tek<sup>+/-</sup></italic> mouse.</p><p>2) Figure 1: Include pTyr signaling in the <italic>Ptprb;Tek</italic> compound heterozygotes. Normalization of pTyr relative to <italic>Tek<sup>+/-</sup></italic> alone would support the conclusion that upregulation of Tie2 signaling is the mechanism of SC/IOP rescue. This could be demonstrated in the eye by western and/or staining.</p><p>3) Figure 2: it would be useful to perform <italic>Tek</italic>, pTek, Prox1, and possibly Ki67 staining in the SC whole mounts, as the authors have done in previous studies. This would support the conclusion that the relative decrease in SC area is associated with defects in <italic>Tek</italic> signaling and subsequent Prox1 activation, as would be expected by the current model of SC development and maintenance. Given the ~two-fold variability in SC area across genotypes, a quantitative correlation may emerge. Short of this, the variability should be discussed.</p><p>4) The authors should show the retinal vascular phenotypes of the <italic>Tek<sup>+/-</sup>, Ptprb</italic><sup>NLS-LacZ/WT</sup> and compound <italic>Tek<sup>+/-</sup>;Ptprb</italic><sup>NLS-LacZ/WT</sup> mice in Figure 2.</p><p>5) Figure 3: Is there a retinal vascular phenotype in the <italic>Ptprb<sup>+/-</sup>, Tek<sup>+/-</sup></italic> and compound heterozygote models? This could influence retinal ganglion cell counts.</p><p>6) The authors should make it clear to the readers that the model they use is a constitutive deletion, thus they describe developmental models rather than conditional gene deletion models. The latter would better mimic a therapeutic model.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48474.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Introduction/Discussion: Clearly state that studied phenotypes are developmental rather than acquired. Alternatively, consider adding IOP studies with VE-PTP inhibitor in the Tek<sup>+/-</sup> mouse.</p></disp-quote><p>Thank you for pointing out where our Discussion was unclear. We have emphasized this important point in the revised manuscript:</p><p>Abstract: “Here, we describe a novel approach to enhance canal formation in these animals by deleting a single allele of the gene encoding the phosphatase PTPRB during development.”</p><p>Introduction: “Here, we show that developmental deletion of a single <italic>Ptprb</italic> allele…”</p><p>Results: “Developmental deletion of a single <italic>Ptprb</italic> allele in <italic>Tek<sup>+/-</sup>;Ptprb</italic><sup>NLS-LacZ/WT</sup> mice…”</p><p>Discussion: “These defects were blunted by developmental <italic>Ptprb</italic> haploinsufficiency in <italic>Tek</italic><sup>+/-</sup>;<italic>Ptprb</italic><sup>NLS-LacZ/WT</sup> mice…”</p><disp-quote content-type="editor-comment"><p>2) Figure 1: Include pTyr signaling in the Ptprb;Tek compound heterozygotes. Normalization of pTyr relative to Tek<sup>+/-</sup> alone would support the conclusion that upregulation of Tie2 signaling is the mechanism of SC/IOP rescue. This could be demonstrated in the eye by western and/or staining.</p></disp-quote><p>We have attempted to quantify levels of <italic>Tek</italic> phosphorylation in Schlemm’s canal endothelium of haploinsufficient mice, but the low levels of total <italic>Tek</italic> in these animals has made it difficult to obtain convincing results. Quantification of immunostaining using phospho-TEK antibodies showed high variability, making it difficult to draw meaningful conclusions. Western blot of eye and lung tissue was similarly complicated by the lower overall level of TEK expression in haploinsufficient animals.</p><p>In light of this difficulty, we have expanded our Discussion to emphasize that while TEK is the most likely substrate, other targets of PTPRB may be implicated in its role in Schlemm’s canal.</p><disp-quote content-type="editor-comment"><p>3) Figure 2: it would be useful to perform Tek, pTek, Prox1, and possibly Ki67 staining in the SC whole mounts, as the authors have done in previous studies. This would support the conclusion that the relative decrease in SC area is associated with defects in Tek signaling and subsequent Prox1 activation, as would be expected by the current model of SC development and maintenance. Given the ~two-fold variability in SC area across genotypes, a quantitative correlation may emerge. Short of this, the variability should be discussed.</p></disp-quote><p>We thank the reviewers for these useful suggestions. We have performed whole mount staining of SC at P5 (during canal development) and at P20 (after development is largely complete). These experiments revealed reduced proliferation of PROX1-positive SC endothelial cells (Ki67/PROX1 double positive cells) in <italic>Tek</italic> haploinsufficient mice compared to control littermates at P5, possibly explaining the smaller Schlemm’s canal observed in these animals. In contrast, <italic>Ptprb/Tek</italic> double heterozygous animals exhibited a normal proportion of Ki67 positive cells, consistent with their increased SC area. This new data has been included in the manuscript as Figure 2B. Likewise, and consistent with previous work from our lab and other groups (Kim et al., 2017), PROX1 expression is reduced in SC of <italic>Tek</italic><sup>+/-</sup> eyes. This reduced PROX1 expression is absent in <italic>Ptprb/Tek</italic> double heterozygous animals, which have normal expression. This data has been included in the manuscript as new Figure 2D.</p><p>The reviewers raised an important point regarding the variability in SC area, especially as seen in <italic>Ptprb/Tek</italic> double heterozygous animals. We have previously reported that <italic>Tek<sup>+/-</sup></italic> mice exhibit a dramatic increase in Schlemm’s canal focal malformations, convolutions and narrowings compared to littermate controls. To address the reviewer’s question, we now include data which clearly shows that while Schlemm’s canal area is substantially larger in <italic>Ptprb/Tek</italic> double heterozygous animals when compared to <italic>Tek<sup>+/-</sup></italic> littermates, this overall morphological phenotype remains—suggesting that ANGPT-TEK signaling may have a guiding role in canal development which is not recapitulated by nonspecific receptor activation. We have included this data in the manuscript as a new Figure 2E.</p><disp-quote content-type="editor-comment"><p>4) The authors should show the retinal vascular phenotypes of the Tek<sup>+/-</sup>, Ptprb<sup>NLS-LacZ/WT</sup> and compound Tek<sup>+/-</sup>;Ptprb<sup>NLS-LacZ/WT</sup> mice in Figure 2.</p></disp-quote><p>We thank the reviewer for raising this important point. We have examined retinal vasculature in littermate mice of all genotypes at P5 (during retinal angiogenesis) and at P20 (after the vascular front has reached the retinal periphery) and found no difference in retinal vascularization. By P20, normal patterning was observed in all three vascular layers and hyaloid vessels were absent in all animals. These new data has been included in the revised manuscript as Figure 3—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>5) Figure 3: Is there a retinal vascular phenotype in the Ptprb<sup>+/-</sup>, Tek<sup>+/-</sup> and compound heterozygote models? This could influence retinal ganglion cell counts.</p></disp-quote><p>Please see our response to question #4 (above). Retinal vasculature appeared normal in all animals examined and we have included these data in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>6) The authors should make it clear to the readers that the model they use is a constitutive deletion, thus they describe developmental models rather than conditional gene deletion models. The latter would better mimic a therapeutic model.</p></disp-quote><p>This is a key point in our manuscript, and we appreciate the feedback that it should be clearer. We have emphasized this point in the revised paper as described in our response to point 1 (above).</p></body></sub-article></article>